BIOVF

$48.21-$0.82 (-1.68%)prev close

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

52-week range

$29.18 – $49.03

96% from low

Exchange

OTC Link

Change+$28.17

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$33.2B	+17.3%	$19.05	$18.32–$20.44	2.5×	1
2027	$37.7B	+13.4%	$24.09	$23.16–$25.85	2.0×	1
2028	$41.7B	+10.8%	$27.48	$26.43–$29.48	1.8×	1
2029	$48.1B	+15.2%	$32.52	$31.28–$34.90	1.5×	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Beat consensus in 7 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-07-16	$0.38	$0.33	-13.5%
2026-04-28	$0.38	$0.45	+17.8%
2026-02-05	$0.46	$0.60	+31.4%
2025-10-20	$0.49	$0.64	+29.9%
2025-07-16	$0.18	$0.24	+35.6%
2025-04-29	$0.22	$0.26	+20.8%
2025-02-05	$0.32	$0.37	+14.4%
2024-10-24	$0.22

Intrinsic value

$140.68

Price

$48.20

Implied upside

+192%

Symbol	Price	Today	Mkt cap	P/E
BIOVFSwedish Orphan Biovitrum AB (publ)	$48.20	+0.00%	$16.7B	—
BDUUYBangkok Dusit Medical Services Public Company Limited	$23.30	+0.00%	$9.3B	—
CHJTFCSPC Pharmaceutical Group Limited	$1.07	+0.00%	$12.2B	—
CSPCYCSPC Pharmaceutical Group Limited	$4.43	+0.68%	$12.8B	—
ERFSFEurofins Scientific SE

No one on the platform currently holds BIOVF.

Institutions holding (13F)

No tracked institution reports a position in BIOVF as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

No one on the platform has traded BIOVF yet.